Scleroderma Therapeutics Market Size
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 5.70 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Scleroderma Therapeutics Market Analysis
The scleroderma therapeutics market is expected to register a CAGR of 5.7% over the forecast period.
The COVID-19 pandemic negatively impacted the global scleroderma therapeutics market. An article published by the journal Lancet Rheumatology in August 2022 reported that COVID-19 led to restrictions that posed a severe challenge to managing pre-existing comorbidities like scleroderma, as doctors and healthcare professionals were busy treating and minimizing COVID-19 infections. However, with the substantial decrease in COVID-19 cases and resumptions of healthcare services, the scleroderma therapeutics market is expected to regain its growth pace. It is projected to show stable growth over the forecast period.
The factors driving the growth of this market are the rising prevalence of scleroderma and the development of novel drug therapies by pharmaceutical companies. An article published by European Medical Journal in May 2022 reported that localized scleroderma (LS) and systemic sclerosis (SSC) are increasing. The incidence of localized scleroderma (LS) in the United States is estimated to be 2.7 out of 100,000 persons. The incidence of systemic sclerosis worldwide is estimated to be 1.4 out of 100,000 person-years in 2021. Thus, the high incidence of this disease is increasing the demand for scleroderma therapeutics, thereby driving the growth of the studied market.
Technological developments have enabled pharmaceutical companies to focus on developing novel drugs. In October 2022, Scleroderma News reported that LMCD1 protein may be a potential novel therapeutic target for patients with SSc-ILD. LMCD1 protein is present at higher levels in the lungs of patients with interstitial lung disease (ILD) linked to systemic sclerosis (SSc) than in healthy individuals. Hence, it is a candidate target for the treatment of the disease. Such novel studies and research for developing novel therapeutics are driving the growth of the studied market.
Similarly, Drug Target Reviews in March 2022 reported that a unique macrophage, an immune cell that removes bacteria or dead cells, plays a vital role in the chronic inflammation and scarring in the lungs and skin of people with scleroderma, or systemic sclerosis. Scientists are targeting this macrophage for the development of drugs. Such studies are leading to the development of novel approaches for treating scleroderma, thereby driving the growth of the studied market.
Thus, due to the rising prevalence of scleroderma and the development of novel drug therapies by pharmaceutical companies, the studied market is expected to witness significant growth over the forecast period. However, regulatory and reimbursement issues may slow down the development of the market.
Scleroderma Therapeutics Market Trends
This section covers the major market trends shaping the Scleroderma Therapeutics Market according to our research experts:
Immunosuppressants Expected to Witness Significant Growth
Immunosuppressant drugs are used to reduce or suppress the immune system's strength. Many research studies have proven significant results of immunosuppressant medications in curing scleroderma. The increasing number of scleroderma cases is also an important factor in the growth of immunosuppressant medications.
In February 2022, an article published in the journal JSRD reported that immunosuppressive drugs, most commonly methotrexate, significantly reduced scleroderma symptoms. Such researches are a positive influence on the studied segment.
Furthermore, developing new drugs by key market players and increasing R&D expenses also promote the development of new molecules for treating immunosuppressant diseases. For instance, in May 2022, NIH reported that the R&D expenses for scleroderma-related research in the United States are estimated to reach USD 22 million by the end of 2022, compared to USD 21 million in 2021, marking a significant increase of 4.7%. Additionally, in October 2022, clinicians at Michigan Medicine and the University of Pittsburgh received USFDA approval for tofacitinib. Tofacitinib, an immunosuppressant drug, has shown promising results in scleroderma patients. Researchers are also optimistic about the next phase of the study.
Thus, due to the significant results of immunosuppressant drugs in curing scleroderma, increasing R&D expenses, and developing new medicines, the segment is expected to witness considerable growth over the forecast period.
North America Expected to Witness Significant Growth
North America is expected to witness significant growth over the forecast period owing to the rising number of people suffering from scleroderma. The developed healthcare sector also allows access to novel therapeutics and drives the studied market's growth.
The presence of non-profit organizations in the region that raise awareness about the disease is also propelling the growth of the studied market. For instance, the National Scleroderma Foundation advances medical research, promotes disease awareness, and provides support and education to people with scleroderma and their families and support networks. This organization aims to educate a larger audience living with scleroderma and connect more people in the community with the resources they need. The National Scleroderma Foundation connects the community of 300,000 Americans living with scleroderma and provides funds for innovative research to discover the cause, understand the mechanism, and overcome the disease. Such initiatives are propelling the growth of the studied market.
Additionally, the increasing research studies in the region are also propelling the market growth. For instance, in January 2022, Paracrine, Inc. received the FDA approval of its Investigational Device Exemption (IDE) to conduct a pivotal trial titled Scleroderma Treatment with Celution Processed Adipose-Derived Regenerative Cells: A Randomized, Double-blind, Placebo-Controlled Study - the "STAR II Trial." The study is designed to provide a robust data set on the safety and efficacy of adipose-derived regenerative cells (ADRCs) in treating patients with hand dysfunction due to diffuse cutaneous scleroderma. Such research studies may lead to the development of disease and thus drive the growth of the market in the region.
In June 2021, Mallinckrodt Pharmaceuticals joined hands with Scleroderma Canada, a non-profit organization. Such joint initiatives by non-profit organizations and pharmaceutical companies raise awareness and provide support and essential resources to people living with scleroderma. Thus, such initiatives are leading to increasing demand for scleroderma therapeutics, thereby driving the growth of the studied market in the region.
Thus, due to the rising number of people suffering from these diseases and the developed healthcare sector, the market is expected to witness significant growth in the region.
Scleroderma Therapeutics Industry Overview
The scleroderma therapeutics market is moderately consolidated due to the presence of a few companies operating globally and regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold market shares and are well-known. These companies are Boehringer Ingelheim International GmbH, Celgene Corporation, Johnson & Johnson Services, Inc., Prometic Life Sciences Inc., Kadmon Holdings Inc., Emerald Health Pharmaceuticals, Cytori Therapeutics Inc., Bayer AG, F. Hoffman La Roche Ltd, arGentis Pharmaceuticals LLC, GlaxoSmithKline PLC, and Novartis AG.
Scleroderma Therapeutics Market Leaders
-
Boehringer Ingelheim International GmbH
-
Celgene Corporation
-
arGentis Pharmaceuticals Llc
-
Kadmon Holdings, Inc.
-
Emerald Health Pharmaceuticals
*Disclaimer: Major Players sorted in no particular order
Scleroderma Therapeutics Market News
- July 2022: Aisa Pharma Inc. reported the positive results of its phase-2 study of Profervia an oral calcium-channel antagonist for the treatment of scleroderma.
- April 2022: aTyr Pharma, Inc. received USFDA approval for efzofitimod used in treating systemic sclerosis.
Scleroderma Therapeutics Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions & Market Definition
1.2 Scope Of The Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Scleroderma
4.2.2 Development of Novel Drugs by Pharmaceutical Companies
4.3 Market Restraints
4.3.1 Regulatory and Reimbursement Issues
4.4 Industry Attractiveness - Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD Million)
5.1 By Disease Type
5.1.1 Systemic Scleroderma
5.1.2 Localized Scleroderma
5.2 By Drug Type
5.2.1 Phosphodiesterase 5 Inhibitors - PHA
5.2.2 Prostacyclin Analogs
5.2.3 Immunosuppressants
5.2.4 Endothelin Receptor Antagonists
5.2.5 Calcium Channel Blockers
5.2.6 Other Drug Types
5.3 By Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Boehringer Ingelheim International GmbH
6.1.2 Celgene Corporation
6.1.3 Johnson & Johnson Services, Inc.
6.1.4 Prometic Life Sciences Inc.
6.1.5 Kadmon Holdings Inc.
6.1.6 Emerald Health Pharmaceuticals
6.1.7 Cytori Therapeutics Inc.
6.1.8 Bayer AG
6.1.9 F. Hoffman La Roche Ltd
6.1.10 arGentis Pharmaceuticals LLC
6.1.11 GlaxoSmithKline PLC (GSK)
6.1.12 Novartis AG
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Scleroderma Therapeutics Industry Segmentation
Scleroderma is an autoimmune disease affecting the skin, blood vessels, muscles, and internal organs. The condition is usually caused due to an abnormal immune response. Therapies for this disease include immunosuppressive drugs and, in some cases, glucocorticoids.
The Scleroderma Therapeutics Market is Segmented by Disease Type (Systemic Scleroderma and Localized Scleroderma), Drug Type (Phosphodiesterase 5 Inhibitors - PHA, Prostacyclin Analogues, Immunosuppressants, Endothelin Receptor Antagonists, Calcium Channel Blockers, and Other Drug Types), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Disease Type | |
| Systemic Scleroderma | |
| Localized Scleroderma |
| By Drug Type | |
| Phosphodiesterase 5 Inhibitors - PHA | |
| Prostacyclin Analogs | |
| Immunosuppressants | |
| Endothelin Receptor Antagonists | |
| Calcium Channel Blockers | |
| Other Drug Types |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Scleroderma Therapeutics Market Research FAQs
What is the current Scleroderma Therapeutics Market size?
The Scleroderma Therapeutics Market is projected to register a CAGR of 5.70% during the forecast period (2024-2029)
Who are the key players in Scleroderma Therapeutics Market?
Boehringer Ingelheim International GmbH, Celgene Corporation, arGentis Pharmaceuticals Llc, Kadmon Holdings, Inc. and Emerald Health Pharmaceuticals are the major companies operating in the Scleroderma Therapeutics Market.
Which is the fastest growing region in Scleroderma Therapeutics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Scleroderma Therapeutics Market?
In 2024, the North America accounts for the largest market share in Scleroderma Therapeutics Market.
What years does this Scleroderma Therapeutics Market cover?
The report covers the Scleroderma Therapeutics Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Scleroderma Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Scleroderma Therapeutics Industry Report
Statistics for the 2024 Scleroderma Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Scleroderma Therapeutics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
